Evidence map›Paper›PMID 41151852›Full record

ArticleCancer genomics & proteomics

Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy.

Yei-Tsung Chen, Pin-Yi Chen, Chi-Fen Chang, Chao-Yuan Huang, Chia-Cheng Yu, Victor C Lin, Hao-Han Chang, Te-Ling Lu, Shu-Pin Huang, Bo-Ying Bao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. ModulatingIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yei-Tsung Chen *Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C.
Pin-Yi Chen *Department of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.
Chi-Fen ChangDepartment of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
Chia-Cheng YuDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
Victor C LinDepartment of Urology, E-Da Hospital, Kaohsiung, Taiwan, R.O.C.
Hao-Han ChangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Te-Ling LuDepartment of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.
Shu-Pin HuangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.; shpihu@kmu.edu.tw bao@mail.cmu.edu.tw.
Bo-Ying BaoDepartment of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.; shpihu@kmu.edu.tw bao@mail.cmu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimProstate cancer, a leading global malignancy, exhibits variable progression influenced by angiogenesis, the formation of new blood vessels critical for tumor growth and metastasis. We investigated the impact of genetic variants of angiogenesis-related genes on the survival outcomes of patients with prostate cancer receiving androgen deprivation therapy (ADT). MATERIALS AND

methodsWe conducted a genetic association study of 87 single-nucleotide polymorphisms across seven angiogenic genes in 630 patients with prostate cancer undergoing ADT. Survival analysis was used to assess progression-free survival (PFS) and overall survival (OS). Functional analyses, including gene ontology and pathway enrichment, were performed to elucidate the underlying biological mechanisms.

results

conclusion

Indexed as

Androgen AntagonistsAngiopoietin-2Neovascularization, PathologicPolymorphism, Single NucleotideProstatic NeoplasmsAgedBiomarkers, TumorHumansMaleMiddle AgedPrognosisAndrogen AntagonistsAngiopoietin-2ANGPT2 protein, humanBiomarkers, Tumorangiogenesisangiopoietingene set enrichment analysisProstate cancersurvival

Identifiers

PMID41151852
PMCPMC12577598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.